ClinicalTrials.gg
TerminatedNCT04422210Updated Nov 8, 2021Results posted

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

A Phase 1 interventional study of Venetoclax and Atezolizumab in Small Cell Lung Cancer, sponsored by Hoffmann-La Roche. Terminated at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-08.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Why this study was terminated
Decision to discontinue the study based on broader development and strategic prioritisation. The Sponsor concludes there is no benefit-risk impact on the GO41864 study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Small Cell Lung Carcinoma by Hoffmann-La Roche — 1 open to participants now, 2 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Hoffmann-La Roche.

Enrollment
14th of 14
2 · median 123
Started
2020
with 3 others
Phase 1
5 of 16
1 open now
Registered
11th of 16
by date

Among the 16 studies in Small Cell Lung Carcinoma by Hoffmann-La Roche, this one is the 14th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2020, is one of 5 in phase 1, and was the 11th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

1 of the 16 studies in Small Cell Lung Carcinoma by Hoffmann-La Roche is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Small Cell Lung Carcinoma by Hoffmann-La Roche, or all of them as a file.
02

Study summary

A study consisting of a dose-escalation phase and a dose-expansion phase to evaluate the safety, tolerability, pharmacokinetics, and efficacy of venetoclax in combination with atezolizumab, carboplatin, and etoposide.

03

Conditions studied

  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Dose Escalation, Maintenance Arm A:

  • Participants with ES-SCLC who have completed 4-6 cycles of carboplatin and etoposide induction chemotherapy, with or without atezolizumab, as their therapy for extensive-stage disease and have responded (CR or PR) or have Stable Disease (SD) are eligible for the maintenance arm of the study.
  • All side effects attributed to prior anti-cancer therapy must have resolved to Grade 1 or baseline.
  • A maximum of 8 weeks (56 days) is allowed between last chemotherapy dose (Cycle 4, Day 3) given in induction and the start of maintenance therapy.

Dose Escalation, Induction Arm B:

  • Participants with no prior systemic treatment for ES-SCLC are eligible for this study.
  • >= 1,500 cells/µL without granulocyte colony-stimulating factor support.

Dose Expansion, Maintenance-Only:

  • Participants with ES-SCLC who have completed 4 cycles of carboplatin and etoposide induction chemotherapy and at least 3 cycles of atezolizumab as their first-line therapy for extensive-stage disease and have responded (CR or PR) or have SD are eligible for the maintenance arm of the study.

Dose Escalation (Arms A and B) and Dose Expansion:

  • Ability to comply with the study protocol, in the investigator's judgement.
  • performance status of 0 or 1.
  • Participants must be able to swallow pills.
  • or cytologically confirmed diagnosis of ES-SCLC per the Veterans Administration Lung Study Group (VALG) staging system.
  • Participants who received prior chemoradiotherapy for limited-stage SCLC must have been treated with curative intent and experienced a treatment-free interval of at least 6 months since last chemotherapy, radiotherapy or chemoradiotherapy cycle prior to diagnosis of ES-SCLC.
  • Participants with a history of treated that are currently asymptomatic.
  • , as defined by v1.1. Baseline measurements and evaluation of all sites of disease must be obtained =\<4 weeks prior to enrollment.
  • Eligible to receive a carboplatin-based chemotherapy regimen.
  • Adequate hematologic and end-organ function.
  • Participants must submit a pre-treatment tumor tissue sample.
  • Participants must submit a blood sample for exploratory biomarker research before treatment, on-study, and following progression of disease.
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse), use non-hormonal methods and refrain from donating eggs.
  • Women who are not (>=12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of study drug.
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom and agreement to refrain from donating sperm.

Exclusion criteria

Exclusion Criteria:

  • Use of non-protocol-specified anti-cancer therapies or other combination partners with carboplatin/etoposide during induction.
  • Symptomatic or actively progressing .
  • Pregnant or breastfeeding, or intending to become pregnant during the study.
  • Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for >= 1 week prior to enrollment.
  • .
  • Uncontrolled pleural effusion, pericardial effusion or ascites requiring recurrent drainage procedures (once a month or more frequently).
  • Uncontrolled or symptomatic hypercalcemia.
  • History of other than SCLC within 5 years prior to enrollment.
  • History of disease.
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
  • Positive infection.
  • Active and C infection (HBV/).
  • Active Tuberculosis infection.
  • Known infection with human T-cell leukemia virus 1.
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization.
  • Significant cardiovascular disease.
  • Major surgical procedure within 28 days prior to enrollment or anticipation of need for major surgical procedure during the course of the study.
  • Prior allogenic bone marrow transplantation or solid organ transplant.
  • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an drug or that may affect the interpretation of the results or render the participant at high risk for treatment complications.
  • Illnesses or conditions that interfere with their capacity to understand, follow, and/or comply with study procedures.
  • Treatment with investigational therapy with therapeutic intent within 28 days prior to enrollment.
  • Administration of a live, attenuated vaccine within 4 weeks before enrollment or anticipation that such a will be required during the study.
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, , and anti-PD-L1 therapeutic antibodies.
  • Treatment with systemic medications within 1 week prior to enrollment.
  • History of severe allergic, anaphylactic, or other reactions to chimeric or humanized antibodies or fusion proteins.
  • Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation.
  • History of allergic reactions to carboplatin or etoposide or to any of its (etoposide).
  • Known hypersensitivity to venetoclax or to any of its excipients.
  • Administration of therapy for anti-neoplastic intent, strong or moderate inhibitors or strong or moderate CYP3A inducers within 7 days prior to the first dose of study drug.
  • Consumption of grapefruit, grapefruit products, Seville oranges (including marmalade-containing Seville oranges), or starfruit (carambola) within 3 days prior to the first dose of study drug.
  • Malabsorption syndrome or other condition that would interfere with enteral absorption.
  • Illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgement.
  • Inability or unwillingness to swallow a large number of tablets.
  • History of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or active bowel inflammation (e.g., diverticulitis).
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Dose Escalation (Arm A1) (Maintenance only)

    Cohort A1: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were administered continuous maintenance therapy with Venetoclax (400mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.

    Drug: Venetoclax · Drug: Atezolizumab

  • Experimental
    Dose Escalation (Arm A2) (Maintenance only)

    Cohort A2: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were to be administered continuous maintenance therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.

    Drug: Venetoclax · Drug: Atezolizumab

  • Experimental
    Dose Escalation (Arm A3) (Maintenance only)

    Cohort A3: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were to be administered continuous maintenance therapy with Venetoclax (200mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1. This cohort maybe explored if Dose-Limiting Toxicities (DLTs) are experienced and adverse events are thought to be potentially mitigated with a lower dose of venetoclax.

    Drug: Venetoclax · Drug: Atezolizumab

  • Experimental
    Dose Escalation (Arm B1) (Induction + Maintenance)

    Cohort B1: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (200mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m\^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).

    Drug: Venetoclax · Drug: Atezolizumab · Drug: Carboplatin · Drug: Etoposide

  • Experimental
    Dose Escalation (Arm B2) (Induction + Maintenance)

    Cohort B2: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (400mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m\^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).

    Drug: Venetoclax · Drug: Atezolizumab · Drug: Carboplatin · Drug: Etoposide

  • Experimental
    Dose Escalation (Arm B3) (Induction + Maintenance)

    Cohort B3: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m\^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).

    Drug: Venetoclax · Drug: Atezolizumab · Drug: Carboplatin · Drug: Etoposide

  • Experimental
    Dose Escalation (Arm B4) (Induction + Maintenance)

    Cohort B4: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 14, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m\^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).

    Drug: Venetoclax · Drug: Atezolizumab · Drug: Carboplatin · Drug: Etoposide

  • Experimental
    Dose Expansion

    If the Recommended Phase II Dose (RP2D) for Venetoclax during induction is established, then the dose-expansion cohort would continue to test venetoclax in both induction and maintenance. Participants would be administered non-continuous induction therapy with Venetoclax (RP2D-I/induction RP2D), Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m\^2) on Days 1-3 followed by continuous maintenance therapy with Venetoclax (RP2D-M) and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1. If significant toxicity and DLTs in induction precluded identification of an RP2D for venetoclax in induction treatment, then the safety and efficacy of venetoclax would only be investigated in dose-expansion in the maintenance setting. Participants would be administered continuous maintenance therapy with Venetoclax (RP2D-M) and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.

    Drug: Venetoclax · Drug: Atezolizumab · Drug: Carboplatin · Drug: Etoposide

Interventions

  • Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.

  • Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.

  • Carboplatin will be administered via IV infusion at a dose of 5mg/mL/min as per the dosing schedules described above.

  • Etoposide will be administered via IV infusion at a dose of 100mg/m\^2 as per the dosing schedules described above.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

    Time frame: Baseline up until 30 days after the last dose of study drug or until initiation of new systemic anti-cancer therapy, whichever occurs first (up to a maximum of 6.5 weeks).

  2. Overall Response Rate (ORR)

    The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

    Time frame: Up to 24 months

Secondary outcomes

  1. Duration of Response (DOR)

    The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

    Time frame: Up to 24 months

  2. Progression Free Survival (PFS)

    The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

    Time frame: Up to 24 months

  3. Overall Survival (OS) After Enrolment

    The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

    Time frame: Up to 49 months

  4. Progression Free Survival (PFS) Rate at 6 Months

    The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

    Time frame: Up to 18 months

  5. Overall Survival (OS) Rate at 1 Year

    The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

    Time frame: Up to 18 months

  6. Plasma Concentrations (ng/mL) of Venetoclax at Specified Timepoints

    The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

    Time frame: Up to 24 months

  7. Serum Concentrations (ng/mL) of Atezolizumab at Specified Timepoints

    The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

    Time frame: Up to 24 months

  8. Plasma Concentrations (ng/mL) of Carboplatin at Specified Timepoints

    The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

    Time frame: Up to 24 months

  9. Plasma Concentrations (ng/mL) of Etoposide at Specified Timepoints

    The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

    Time frame: Up to 24 months

07

Results

Posted Nov 8, 2021
Limitations and caveats
The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Participant flow

Participant flow — Overall Study
MilestoneDose Escalation (Arm A1) (Maintenance Only)Dose Escalation (Arm A2) (Maintenance Only)Dose Escalation (Arm A3) (Maintenance Only)Dose Escalation (Arm B1) (Induction + Maintenance)Dose Escalation (Arm B2) (Induction + Maintenance)Dose Escalation (Arm B3) (Induction + Maintenance)Dose Escalation (Arm B4) (Induction + Maintenance)Dose Expansion
Started00000000
Completed00000000
Not completed00000000

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Time frame:
Baseline up until 30 days after the last dose of study drug or until initiation of new systemic anti-cancer therapy, whichever occurs first (up to a maximum of 6.5 weeks).

No measurements were reported for this outcome.

PrimaryOverall Response Rate (ORR)

The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Time frame:
Up to 24 months

No measurements were reported for this outcome.

SecondaryDuration of Response (DOR)

The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Time frame:
Up to 24 months

No measurements were reported for this outcome.

SecondaryProgression Free Survival (PFS)

The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Time frame:
Up to 24 months

No measurements were reported for this outcome.

SecondaryOverall Survival (OS) After Enrolment

The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Time frame:
Up to 49 months

No measurements were reported for this outcome.

SecondaryProgression Free Survival (PFS) Rate at 6 Months

The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Time frame:
Up to 18 months

No measurements were reported for this outcome.

SecondaryOverall Survival (OS) Rate at 1 Year

The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Time frame:
Up to 18 months

No measurements were reported for this outcome.

SecondaryPlasma Concentrations (ng/mL) of Venetoclax at Specified Timepoints

The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Time frame:
Up to 24 months

No measurements were reported for this outcome.

SecondarySerum Concentrations (ng/mL) of Atezolizumab at Specified Timepoints

The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Time frame:
Up to 24 months

No measurements were reported for this outcome.

SecondaryPlasma Concentrations (ng/mL) of Carboplatin at Specified Timepoints

The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Time frame:
Up to 24 months

No measurements were reported for this outcome.

SecondaryPlasma Concentrations (ng/mL) of Etoposide at Specified Timepoints

The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Time frame:
Up to 24 months

No measurements were reported for this outcome.

Adverse events

Collected over The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation (Arm A1) (Maintenance Only)———
Dose Escalation (Arm A2) (Maintenance Only)———
Dose Escalation (Arm A3) (Maintenance Only)———
Dose Escalation (Arm B1) (Induction + Maintenance)———
Dose Escalation (Arm B2) (Induction + Maintenance)———
Dose Escalation (Arm B3) (Induction + Maintenance)———
Dose Escalation (Arm B4) (Induction + Maintenance)———
Dose Expansion———

Baseline characteristics

The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Age, Continuous
Age, Continuous(years)Dose Escalation (Arm A1) (Maintenance Only)Dose Escalation (Arm A2) (Maintenance Only)Dose Escalation (Arm A3) (Maintenance Only)Dose Escalation (Arm B1) (Induction + Maintenance)Dose Escalation (Arm B2) (Induction + Maintenance)Dose Escalation (Arm B3) (Induction + Maintenance)Dose Escalation (Arm B4) (Induction + Maintenance)Dose ExpansionTotal
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation (Arm A1) (Maintenance Only)Dose Escalation (Arm A2) (Maintenance Only)Dose Escalation (Arm A3) (Maintenance Only)Dose Escalation (Arm B1) (Induction + Maintenance)Dose Escalation (Arm B2) (Induction + Maintenance)Dose Escalation (Arm B3) (Induction + Maintenance)Dose Escalation (Arm B4) (Induction + Maintenance)Dose ExpansionTotal
Female—————————
Male—————————
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Escalation (Arm A1) (Maintenance Only)Dose Escalation (Arm A2) (Maintenance Only)Dose Escalation (Arm A3) (Maintenance Only)Dose Escalation (Arm B1) (Induction + Maintenance)Dose Escalation (Arm B2) (Induction + Maintenance)Dose Escalation (Arm B3) (Induction + Maintenance)Dose Escalation (Arm B4) (Induction + Maintenance)Dose ExpansionTotal
08

Study locations

5 sites
  • Emory University
    Atlanta, Georgia 30322, United States
  • Rigshospitalet; Onkologisk Klinik
    København Ø, 2100, Denmark
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • ICO I Hospitalet Hospital Duran i Reynals Instituto Catalan de Oncologia de Hospitalet ICO
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
  • START Madrid. Centro Integral Oncologico Clara Campal; CIOCC
    Madrid, 28050, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Nov 2020, 1 month.

Results were first posted in Nov 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2020
First posted
Jun 9, 2020
StartActual
Sep 22, 2020
Primary completionActual
Nov 6, 2020
CompletionActual
Nov 6, 2020
Results first posted
Nov 8, 2021
Last update
Nov 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04422210
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 9, 2020
Start date
Sep 22, 2020
Primary completion
Nov 6, 2020
Completion
Nov 6, 2020
Results posted
Nov 8, 2021
Last update
Nov 8, 2021

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion